Placebo News and Research

RSS

Adding veliparib to chemotherapy can extend progression-free survival in patients with “BRCA-like” breast cancer

Results from the SWOG S1416 clinical trial show that adding veliparib to chemotherapy can significantly extend progression-free survival (PFS) times in patients with triple-negative breast cancer (TNBC) that has a "BRCA-like" phenotype.

31 Jan 2023

Patients with myelofibrosis show improvement in disease-related symptoms when treated with momelotinib

Patients with myelofibrosis had clinically significant improvement in disease-related symptoms, including anemia and spleen enlargement, when treated with the targeted therapy momelotinib, according to results from the international Phase III MOMENTUM trial led by researchers at The University of Texas MD Anderson Cancer Center.

29 Jan 2023

Nitrate boost causes an increase in muscle force during exercise

A new study has found that consuming dietary nitrate – the active molecule in beetroot juice – significantly increased muscle force while exercising.

23 Jan 2023

Scientists reveal why common anti-depressants cause emotional ‘blunting’ in users

Scientists have worked out why common anti-depressants cause around a half of users to feel emotionally 'blunted'.

23 Jan 2023

Long-term, COVID-19-related smell loss could be treated using injections of platelet-rich plasma

Early in the pandemic, when people with COVID-19 began reporting that they lost their sense of smell, Zara Patel, MD, figured as much. A professor of otolaryngology at Stanford Medicine, Patel has, for years, studied loss of smell as a symptom of viral infections.

19 Jan 2023

Overweight people have a different vitamin D metabolism

A new study in JAMA Network Open aimed to determine whether BMI is capable of modifying vitamin D metabolism as well as response to supplementation.

18 Jan 2023

Investigational vaccine regimen safe but did not provide protection against HIV acquisition

An investigational HIV vaccine regimen tested among men who have sex with men (MSM) and transgender people was safe but did not provide protection against HIV acquisition, an independent data and safety monitoring board (DSMB) has determined.

18 Jan 2023

The efficacy of low-dose fluvoxamine compared with placebo for treating mild to moderate COVID-19 in the US

Researchers evaluated the efficacy of low-dosage fluvoxamine (50 mg two times a day) over 10 days in the management of mild and moderate-SARS-CoV-2 infections in the US.

18 Jan 2023

Probiotic diminishes S. aureus bacterial colonization, Phase 2 trial shows

A promising approach to control Staphylococcus aureus bacterial colonization in people - using a probiotic instead of antibiotics - was safe and highly effective in a Phase 2 clinical trial.

17 Jan 2023

Simple nasal spray effective at easing sleep-disordered breathing in children

A simple nasal spray significantly reduced snoring and breathing difficulties in children and halved the number needing to have their tonsils removed, according to a new study.

17 Jan 2023

Acupuncture could be a safe and feasible management option for IBS-D

Researchers preliminarily evaluated the practicality of utilizing the United States (US) Food and Drug Administration (FDA)-advocated endpoints to assess the effectiveness of acupuncture in IBS-D (irritable bowel syndrome with diarrhea) management.

5 Jan 2023

Study demonstrates safety and efficacy of a three-dose whole-parasite vaccine against malaria

A three-dose regimen of a whole-parasite vaccine against malaria – called Plasmodium falciparum sporozoite (PfSPZ) vaccine – demonstrated safety and efficacy when tested in adults living in Burkina Faso, West Africa, which has endemic malaria.

4 Jan 2023

How could probiotics be used in the management of gingivitis and periodontitis?

New research explores how probiotic-based therapy in conjunction with established treatment regimens can be an effective approach for combating gingivitis and periodontitis.

28 Dec 2022

Molnupiravir does not reduce hospitalization or deaths in vaccinated adults with COVID-19, but improves recovery

Molnupiravir (taken as an 800mg dose twice daily for five days) does not reduce hospital admissions or deaths in vaccinated adults with COVID-19 infection who are at higher risk of mortality, according to the results of a randomised controlled trial, published in The Lancet journal.

23 Dec 2022

Clinical trials demonstrate safety and efficacy of Ebola Zaire vaccines

Two vaccines against the Zaire strain of Ebola virus are immunogenic and safe in both adults and children, according to initial results from two phase II clinical trials published in the New England Journal of Medicine.

21 Dec 2022

Trial of three vaccines for Zaire Ebola virus disease

Researchers perform two randomized controlled trials to determine immunogenicity and safety of three Ebola vaccines.

20 Dec 2022

Can ivermectin improve the duration of sustained recovery among COVID-19 outpatients?

Researchers assessed the impact of ivermectin on the duration of sustained recovery among coronavirus disease 2019 (COVID-19) outpatients.

20 Dec 2022

Dapagliflozin improves morbidity reduces risk of death in heart failure patients

Researchers investigate the safety and efficacy of dapagliflozin among heart failure patients with improved ejection fraction.

19 Dec 2022

Low ET levels in blood plasma may predict increased risk of cognitive impairment, dementia

A recent study by a team comprising researchers from the National University of Singapore and the National University Health System revealed that low levels of ergothioneine in blood plasma may predict an increased risk of cognitive impairment and dementia, suggesting possible therapeutic or early screening measures for cognitive impairment and dementia in the elderly.

19 Dec 2022

Trial results confirm the safety of three different Ebola vaccine regimens

Ebola epidemics occur periodically in various sub-Saharan African countries. While vaccines exist and have already received WHO Prequalification against the Zaire ebolavirus species, it is essential to pursue and intensify efforts to supplement the available data to develop a safe and effective Ebola vaccine strategies in adults and children alike.

16 Dec 2022

Placebo News and Research

Adding veliparib to chemotherapy can extend progression-free survival in patients with “BRCA-like” breast cancer

Patients with myelofibrosis show improvement in disease-related symptoms when treated with momelotinib

Nitrate boost causes an increase in muscle force during exercise

Scientists reveal why common anti-depressants cause emotional ‘blunting’ in users

Long-term, COVID-19-related smell loss could be treated using injections of platelet-rich plasma

Overweight people have a different vitamin D metabolism

Investigational vaccine regimen safe but did not provide protection against HIV acquisition

The efficacy of low-dose fluvoxamine compared with placebo for treating mild to moderate COVID-19 in the US

Probiotic diminishes S. aureus bacterial colonization, Phase 2 trial shows

Simple nasal spray effective at easing sleep-disordered breathing in children

Acupuncture could be a safe and feasible management option for IBS-D

Study demonstrates safety and efficacy of a three-dose whole-parasite vaccine against malaria

How could probiotics be used in the management of gingivitis and periodontitis?

Molnupiravir does not reduce hospitalization or deaths in vaccinated adults with COVID-19, but improves recovery

Clinical trials demonstrate safety and efficacy of Ebola Zaire vaccines

Trial of three vaccines for Zaire Ebola virus disease

Can ivermectin improve the duration of sustained recovery among COVID-19 outpatients?

Dapagliflozin improves morbidity reduces risk of death in heart failure patients

Low ET levels in blood plasma may predict increased risk of cognitive impairment, dementia

Trial results confirm the safety of three different Ebola vaccine regimens

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News